Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

TNXP stock hub

Tonix Pharmaceuticals Holding Corp. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

TNXPis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

200.2M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

TNXP

In the news

Latest news · TNXP

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-64.5

P25 -105.6P50 -46.5P75 -3.1

ROIC-39.9

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All TNXP market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

202

Groups with data

Currency

USD

Showing 202 of 202 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001430306
Company name	Tonix Pharmaceuticals Holding Corp.
Country	United States
Country code	US
Cusip	890260839
Employees	142
Employees Change	61%
Employees Change Percent	75.31
Enterprise value	$-6.2M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US8902608392
Last refreshed	2026-05-10
Market cap	$200.2M
Market cap category	Micro-Cap
Price	$14.09
Price currency	USD
Rev Per Employee	92,302.82x
Sector	Healthcare
Sic	2834
Symbol	TNXP
Website	https://www.tonixpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-61.96%
FCF yield	-51.57%
P/B ratio	0.73x
P/S ratio	15.27x
PS Forward	2.37x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	49.34%
Gross Profit	$6.5M
Gross Profit Growth	177.67%
Gross Profit Growth Q	209.65%
Net Income	$-124M
Net Income Growth Years	1%
Pretax Margin	-946.22%
Profit Per Employee	$-873,387
ROA	-35.71
Roa5y	-33.86
ROCE	-51.03
ROE	-64.48
Roe5y	-71.44
ROIC	-39.87

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-83.92%
Cagr1y	-26.4%
Cagr3y	-88.89%
Cagr5y	-88.45%
EPS Growth Years	10
Revenue Growth	29.85x
Revenue Growth Q	108.75x
Revenue Growth Quarters	2x
Revenue Growth Years	2x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.06
Assets	$277.2M
Cash	$207.6M
Current Assets	$228.9M
Current Liabilities	$30.8M
Debt	$1.3M
Debt Equity	$0.01
Equity	$245.2M
Interest Coverage	-1,412.4
Liabilities	$32M
Long Term Assets	$48.3M
Long Term Liabilities	$1.2M
Net Cash	$206.3M
Net Cash By Market Cap	$103
Net Cash Growth	127.59%
Net Debt Equity	$-0.84
Tangible Book Value	$245M
Tangible Book Value Per Share	$19.16
WACC	13.47

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	7.42
Inventory Turnover	0.86
Net Working Capital	$-9.5M
Quick ratio	6.96
Working Capital	$198M
Working Capital Turnover	$0.09

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-1,055.9%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-100%
1Y total return	-26.38%
200-day SMA	20.96
3Y total return	-99.86%
50-day SMA	13.7
50-day SMA vs 200-day SMA	50under200
5Y total return	-100%
All Time High	20,600,000,000
All Time High Change	-100%
All Time High Date	2012-02-08
All Time Low	6.76
All Time Low Change	108.43%
All Time Low Date	2025-03-04
ATR	0.92
Beta	1.69
Beta1y	3.22
Beta2y	1.48
Ch YTD	-9.8
High	14.14
High52	69.97
High52 Date	2025-08-14
High52ch	-79.86%
Low	13.52
Low52	11.6
Low52 Date	2026-03-30
Low52ch	21.43%
Ma50ch	2.83%
Premarket Change Percent	2.13
Premarket Price	$13.91
Premarket Volume	1,583
Price vs 200-day SMA	-32.79%
RSI	53.81
RSI Monthly	29.83
RSI Weekly	41.67
Sharpe ratio	0.1x
Sortino ratio	0.24
Total Return	-1,055.9%
Tr YTD	-9.8
Tr1m	7.8%
Tr1w	3.6%
Tr3m	-13.77%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	1
Analyst Ratings	Strong Buy
Earnings EPS Estimate	$-2.51
Earnings Revenue Estimate	7,420,000x
Earnings Revenue Estimate Growth	205.48x
Operating Income	$-125.7M
Operating margin	-959.1
Price target	$22
Price Target Change	$56.14

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	14,180,024%
Float Percent	99.82%
Net Borrowing	-9,650,000
Shares Insiders	0.18%
Shares Institutions	26.73%
Shares Out	14,205,401
Shares Qo Q	32.23%
Shares Yo Y	1,055.9%
Short Float	17.46%
Short Ratio	4.77
Short Shares	17.43

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-109.2M
Average Volume	412,152.65x
Bv Per Share	19.17
CAPEX	$-3.4M
Ch10y	-100
Ch1m	7.8
Ch1w	3.6
Ch1y	-26.38
Ch3m	-13.77
Ch3y	-99.86
Ch5y	-100
Ch6m	-17.12
Change	3.45%
Change From Open	2.85
Close	13.62
Days Gap	0.59
Depreciation Amortization	1,925,000
Dollar Volume	3,704,148.3
Earnings Date	2026-05-11
Earnings Time	amc
EBIT	$-125.7M
EBITDA	$-123.8M
EPS	$-14.57
F Score	3
FCF	$-103.2M
FCF EV Yield	1,671.76x
FCF Per Share	$-7.27
Financing CF	214,530,000
Fiscal Year End	December
Founded	2,007
Investing CF	-4,528,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-12
Last Report Date	2025-12-31
Last Split Date	2025-02-05
Last Split Type	Reverse
Last10k Filing Date	2026-03-12
Ma150	16.21
Ma150ch	-13.07%
Ma20	13.41
Ma20ch	5.05%
Net CF	110,127,000
Next Earnings Date	2026-05-22
Open	13.7
Optionable	Yes
Position In Range	91.94
Post Close	14.09
Postmarket Change Percent	-0.07
Postmarket Price	$14.08
Ppne	46,000,000
Pre Close	13.62
Price Date	2026-05-08
Ptbv Ratio	0.82
Relative Volume	0.64x
Revenue	13,107,000x
SBC By Revenue	45.91x
Share Based Comp	6,017,000
Tr6m	-17.12%
Us State	New Jersey
Volume	262,892
Z Score	-1.26

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does TNXP pay a dividend?

Capital-return profile for this ticker.

Performance

TNXP stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns TNXP?

Insider, institutional, and short-interest positioning.

Institutional ownership

+26.7%

Float: +99.8% of shares outstanding

Insider ownership

+0.2%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

TNXP momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

53.8

Neutral momentum band

Price vs 200-day MA

-32.8%

50/200-day relationship not available

Beta (5Y)

1.69

More volatile than the market

Sharpe ratio

0.10

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About TNXP

Hub-level FAQ points readers to the deeper analysis pages.

What is the current TNXP stock rating?

Tonix Pharmaceuticals Holding Corp. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full TNXP analysis?

The full report lives at /stocks/TNXP/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for TNXP?

The latest report frames TNXP around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the TNXP page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.